AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc.

In a report released on September 21, Trung Huynh from RBC Capital maintained a Buy rating on AbbVie, with a price target of $280.00. The company’s...

RBC Capital Sticks to Its Buy Rating for AbbVie (ABBV)

ADARx Pharmaceuticals, which is using RNA technology to fight diseases like Alzheimer’s, is targeting a valuation of up to $1.74 billion in its U.S...

Alzheimer’s-Fighting ADARx Pharmaceuticals Set for Near $2B IPO

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie’s latest dry eye study compares its new ABBV-444 artificial tear against...

AbbVie Targets Dry Eye Market Upside With New ABBV-444 Trial Update

RBC Capital analyst Trung Huynh maintained a Buy rating on AbbVie yesterday and set a price target of $280.00. According to TipRanks, Huynh is a 5-...

RBC Capital Sticks to Their Buy Rating for AbbVie (ABBV)

Abbvie ($ABBV) announced an update on their ongoing clinical study. The AbbVie Inc. (ABBV) ECLIPSE study, officially titled “Randomized, Double-bli...

AbbVie’s ECLIPSE Migraine Trial Completes, Setting Up a New Catalyst for ABBV

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alcon (ALC) and AbbVie (ABBV) with bullish sentiment...

Analysts Offer Insights on Healthcare Companies: Alcon (ALC) and AbbVie (ABBV)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Adagene (ADAG), AbbVie (ABBV) and Definium Therapeut...

Analysts’ Top Healthcare Picks: Adagene (ADAG), AbbVie (ABBV)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AbbVie (ABBV) and Pyxis Oncology (PYXS) with bullish...

Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Pyxis Oncology (PYXS)

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie is reporting new data from an observational eye study in adults with dia...

AbbVie’s Eye Implant Study Delivers Fresh Real‑World Clarity for Investors

RedHill Biopharma ($RHDL) has said the acquisition from Ferring of commercialization rights to two established gastrointestinal (GI) FDA-approved d...

RedHill Biopharma Pushes for Growth Securing Rights to Ferring’s $37M Gastrointestinal Drugs Portfolio

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Annovis Bio (ANVS), AbbVie (ABBV) and Glaukos (GKOS)...

Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbbVie (ABBV)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Legend Biotech (LEGN), Ionis Pharmaceuticals (IONS...

Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Ionis Pharmaceuticals (IONS) and AbbVie (ABBV)

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) has posted a new Phase 3 trial plan for its drug etentamig in amy...

AbbVie Targets Rare Blood Disorder With New Phase 3 Etentamig Trial Plan

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) is running a new Phase 2 platform basket study called “A Phase 2 ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ABBV	$264.34	-0.29%	2.54M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ABBV	$264.34	-0.3%	2.54M
3
4
5
6

ABBV

Get AbbVie Inc. Data in Excel

Get AbbVie Inc. Data in Excel